Literature DB >> 11169446

Improvement in affinity and HIV-1 neutralization by somatic mutation in the heavy chain first complementarity-determining region of antibodies triggered by HIV-1 infection.

J L Torán1, L Sánchez-Pulido, L Kremer, G del Real, A Valencia, C Martínez-A.   

Abstract

We assessed the impact of somatic hypermutation in the framework region 1 (FR1) and complementarity-determining region 1 (CDR1) of three clonally-related heavy chains from the human monovalent antigen-binding fragments Fab S19, S8 and S20 on gp120 binding and HIV-1 neutralization capacity. Nucleotide changes were introduced in the heavy chains to revert single and multiple amino acid residues, and two Fab libraries were constructed with the same light chain to express equivalent amounts of parental and reverted phage Fab. We studied the contribution of each amino acid replacement to antigen binding by calculating the frequency of phage Fab retrieval after competitive library selection on gp120. Whereas mutations in FR1 had no effect on antigen binding, somatic replacements in the CDR1 of the heavy chain (HCDR1) appeared to produce significant changes. In S19 HCDR1, somatic mutation of residue 32 reduced gp120 binding. In Fab S20, the Arg(30) and Asp(31) somatically replaced residues in HCDR1 improved antigen binding. Both of these residues are necessary to increase Fab binding to gp120; reversion of either residue alone results in a decrease in binding. The impact of these two replacements was confirmed by the greater neutralization capacity of S20 compared to the other Fab. Molecular modeling of S20 HCDR1 suggests that Arg(30) and Asp(31) are the main interaction sites for gp120, increasing antibody affinity and promoting the enhanced neutralization ability of S20. These findings are consistent with a gp120-driven process, supporting a role for affinity maturation and intraclonal evolution of HIV-1 neutralizing antibodies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11169446     DOI: 10.1002/1521-4141(200101)31:1<128::aid-immu128>3.0.co;2-t

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  3 in total

Review 1.  Genetic and structural determinants of virus neutralizing antibodies.

Authors:  J E Crowe; R O Suara; S Brock; N Kallewaard; F House; J H Weitkamp
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

2.  Increased antibody affinity confers broad in vitro protection against escape mutants of severe acute respiratory syndrome coronavirus.

Authors:  Mridula Rani; Meagan Bolles; Eric F Donaldson; Thomas Van Blarcom; Ralph Baric; Brent Iverson; George Georgiou
Journal:  J Virol       Date:  2012-06-13       Impact factor: 5.103

Review 3.  Phages and HIV-1: from display to interplay.

Authors:  Sylvie Delhalle; Jean-Claude Schmit; Andy Chevigné
Journal:  Int J Mol Sci       Date:  2012-04-13       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.